Literature DB >> 29762166

Undisclosed antiretroviral drug use in Botswana: implication for national estimates.

Sikhulile Moyo1,2, Simani Gaseitsiwe1,2, Kathleen M Powis1,2,3, Molly Pretorius Holme1,2, Terence Mohammed1, Melissa Zahralban-Steele2, Etienne K Yankinde1, Comfort Maphorisa1, William Abrams4, Refeletswe Lebelonyane5, Kutlo Manyake1, Tumalano Sekoto1, Mompati Mmalane1, Tendani Gaolathe1, Kathleen E Wirth2, Joseph Makhema1, Shahin Lockman1,2,6, William Clarke7, Max Essex1,2, Vlad Novitsky1,2.   

Abstract

: Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29762166      PMCID： PMC6047897          DOI： 10.1097/QAD.0000000000001862

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  23 in total

1.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).

Authors:  Jessica M Fogel; Lei Wang; Teresa L Parsons; San-San Ou; Estelle Piwowar-Manning; Ying Chen; Victor O Mudhune; Mina C Hosseinipour; Johnstone Kumwenda; James G Hakim; Suwat Chariyalertsak; Ravindre Panchia; Ian Sanne; Nagalingeswaran Kumarasamy; Beatriz Grinsztejn; Joseph Makhema; Jose Pilotto; Breno R Santos; Kenneth H Mayer; Marybeth McCauley; Theresa Gamble; Namandjé N Bumpus; Craig W Hendrix; Myron S Cohen; Susan H Eshleman
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

3.  Unreported antiretroviral use by HIV-1-infected participants enrolling in a prospective research study.

Authors:  Erin M Kahle; Angela Kashuba; Jared M Baeten; Kenneth H Fife; Connie Celum; Andrew Mujugira; Max Essex; Guy De Bruyn; Anna Wald; Deborah Donnell; Grace John-Stewart; Sinead Delany-Moretlwe; Nelly R Mugo; Carey Farquhar; Jairam R Lingappa
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

4.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

Review 5.  Elite control of HIV Infection: implications for vaccines and treatment.

Authors:  Bruce D Walker
Journal:  Top HIV Med       Date:  2007 Aug-Sep

6.  Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from National HIV Behavioral Surveillance, 2004-2011.

Authors:  Moupali Das; H F Raymond; Priscilla Chu; Israel Nieves-Rivera; Mark Pandori; Brian Louie; Leah Rauch; Susan Scheer; Eric Vittinghoff; Willi McFarland
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

Review 7.  Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review.

Authors:  Reuben Granich; Somya Gupta; Irene Hall; John Aberle-Grasse; Shannon Hader; Jonathan Mermin
Journal:  PLoS Med       Date:  2017-04-04       Impact factor: 11.069

8.  Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey.

Authors:  Peter Cherutich; Andrea A Kim; Timothy A Kellogg; Kenneth Sherr; Anthony Waruru; Kevin M De Cock; George W Rutherford
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

9.  Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literature.

Authors:  Trevor A Crowell; Hiroyu Hatano
Journal:  J Virus Erad       Date:  2015-04

10.  A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.

Authors:  Helena Huerga; Fisseha Shiferie; Eduard Grebe; Ruggero Giuliani; Jihane Ben Farhat; Gilles Van-Cutsem; Karen Cohen
Journal:  BMC Infect Dis       Date:  2017-09-29       Impact factor: 3.090
View more
  9 in total

Review 1.  Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era.

Authors:  Suzanne M McCluskey; Toby Pepperrell; Andrew Hill; Willem D F Venter; Ravindra K Gupta; Mark J Siedner
Journal:  AIDS       Date:  2021-12-15       Impact factor: 4.177

2.  HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART).

Authors:  Jessica M Fogel; Ethan A Wilson; Estelle Piwowar-Manning; Autumn Breaud; William Clarke; Christos Petropoulos; Ayana Moore; Christophe Fraser; Barry Kosloff; Kwame Shanaube; Gert van Zyl; Michelle Scheepers; Sian Floyd; Peter Bock; Helen Ayles; Sarah Fidler; Richard Hayes; Deborah Donnell; Susan H Eshleman
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707

3.  High Level of HIV Drug Resistance and Virologic Nonsuppression Among Female Sex Workers in Ethiopia: A Nationwide Cross-Sectional Study.

Authors:  Dawit Assefa Arimide; Minilik Demissie Amogne; Yenew Kebede; Taye T Balcha; Fekadu Adugna; Artur Ramos; Joshua DeVos; Clement Zeh; Anette Agardh; Joy Chih-Wei Chang; Per Björkman; Patrik Medstrand
Journal:  J Acquir Immune Defic Syndr       Date:  2022-04-15       Impact factor: 3.771

Review 4.  Pharmacology of HIV Cure: Site of Action.

Authors:  Aaron S Devanathan; Mackenzie L Cottrell
Journal:  Clin Pharmacol Ther       Date:  2021-03-05       Impact factor: 6.875

5.  Undisclosed HIV status and antiretroviral therapy use among South African blood donors.

Authors:  Karin van den Berg; Marion Vermeulen; Vernon J Louw; Edward L Murphy; Gary Maartens
Journal:  Transfusion       Date:  2021-07-05       Impact factor: 3.337

6.  Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.

Authors:  Benjamin Chimukangara; Richard J Lessells; Soo-Yon Rhee; Jennifer Giandhari; Ayesha B M Kharsany; Kogieleum Naidoo; Lara Lewis; Cherie Cawood; David Khanyile; Kassahun A Ayalew; Karidia Diallo; Reshmi Samuel; Gillian Hunt; Alain Vandormael; Babill Stray-Pedersen; Michelle Gordon; Tariro Makadzange; Photini Kiepiela; Gita Ramjee; Johanna Ledwaba; Monalisa Kalimashe; Lynn Morris; Urvi M Parikh; John W Mellors; Robert W Shafer; David Katzenstein; Pravi Moodley; Ravindra K Gupta; Deenan Pillay; Salim S Abdool Karim; Tulio de Oliveira
Journal:  EClinicalMedicine       Date:  2019-03-18

7.  Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.

Authors:  Sikhulile Moyo; Simani Gaseitsiwe; Melissa Zahralban-Steele; Dorcas Maruapula; Tapiwa Nkhisang; Baitshepi Mokaleng; Terence Mohammed; Tsotlhe R Ditlhako; Ontlametse T Bareng; Thatayaone P Mokgethi; Erik van Widenfelt; Molly Pretorius-Holme; Madisa O Mine; Elliot Raizes; Etienne Kadima Yankinda; Kathleen E Wirth; Tendani Gaolathe; Joseph M Makhema; Shahin Lockman; Max Essex; Vlad Novitsky
Journal:  AIDS       Date:  2019-05-01       Impact factor: 4.177

8.  Rapid emergence of resistance to antiretroviral treatment after undisclosed prior exposure: A case report.

Authors:  Theresa M Rossouw; Gisela van Dyk; Gert van Zyl
Journal:  South Afr J HIV Med       Date:  2019-07-30       Impact factor: 2.744

9.  Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural KwaZulu Natal South Africa: A DO-ART Trial Sub-study.

Authors:  Nsika Sithole; Resign Gunda; Olivier Koole; Meighan Krows; Torin Schaafsma; Mosa Moshabela; Mark J Siedner; Connie Celum; Ruanne V Barnabas
Journal:  AIDS Behav       Date:  2021-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.